Teva's Mark Sabag exercises options, sells 46K shares

The reported sale price was a weighted average across transactions ranging from $41.81 to $42.08 per share.

Available on EDGAR 11/06/2026 - 04:04 PM EST Accepted by SEC EDGAR 11/06/2026 - 04:03 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Mark Sabag, TEVA’s Executive Vice President, International Markets Commercial, exercised 46,000 stock options on November 5, 2026, at an exercise price of $34.90 per share, acquiring 46,000 ordinary shares. He sold those shares the same day at a weighted average price of $41.9289 per share; the reported sale prices ranged from $41.81 to $42.08. The reported post-transaction stock-option balance was 44,710 options.

Insider Trade Summary

Exercise and Sale: 46,000 shares ($323K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Sabag Mark

Role See "Remarks"

Sold 46,000 shs ($1.93M)

Approx. gross sale proceeds $1.93M

Approx. exercise cost $1.61M

Approx. pre-tax spread $323K

Type	Security	Shares	Price	Value
Exercise	Stock Options (right to buy) F2	46,000	$0.00	$0.00
Exercise	Ordinary Shares	46,000	$34.90	$1.61M
Sale	Ordinary Shares F1	46,000	$41.9289	$1.93M

Holdings After Transaction: Stock Options (right to buy) — 44,710 contracts (Direct); Ordinary Shares — 80,760 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.81 to $42.08, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
2. F2. Stock options were granted on February 14, 2017, with 30,236 vested on each of February 14, 2018, February 14, 2019 and February 14, 2020, and 30,238 vested on February 14, 2021.

Key Figures

Stock options exercised: 46,000 options Exercise price: $34.90 per share Ordinary shares acquired: 46,000 shares +4 more

7 metrics

Stock options exercised 46,000 options November 5, 2026

Exercise price $34.90 per share Options exercised November 5, 2026

Ordinary shares acquired 46,000 shares Upon option exercise on November 5, 2026

Ordinary shares sold 46,000 shares November 5, 2026

Weighted average sale price $41.9289 per share Sale on November 5, 2026

Sale price range $41.81 to $42.08 per share Multiple sale transactions; inclusive

Stock options after exercise 44,710 options Reported following the November 5, 2026 transaction

Key Terms

weighted average price, exercise price, stock options, vested

4 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

exercise price financial

"conversion_or_exercise_price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

stock options financial

"Stock options were granted on February 14, 2017"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

vested financial

"30,236 vested on each of February 14, 2018"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TEVA options did Mark Sabag exercise, and at what price?

Mark Sabag exercised 46,000 stock options on November 5, 2026, at an exercise price of $34.90 per share, acquiring 46,000 ordinary shares.

How many TEVA shares did Mark Sabag sell and at what price?

Mark Sabag sold 46,000 ordinary shares on November 5, 2026, at a weighted average price of $41.9289 per share. The shares were sold in multiple transactions at prices ranging from $41.81 to $42.08, inclusive. No Rule 10b5-1 plan is reported.

What was the vesting schedule for Mark Sabag’s TEVA options?

The stock options were granted on February 14, 2017. 30,236 options vested on each of February 14, 2018, February 14, 2019, and February 14, 2020, and 30,238 vested on February 14, 2021.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sabag Mark

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See "Remarks"

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	11/05/2026		M		46,000	A	$34.9	126,760	D
Ordinary Shares	11/05/2026		S		46,000	D	$41.9289(1)	80,760	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$34.9	11/05/2026		M			46,000	(2)	02/14/2027	Ordinary Shares	46,000	$0	44,710	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.81 to $42.08, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

2. Stock options were granted on February 14, 2017, with 30,236 vested on each of February 14, 2018, February 14, 2019 and February 14, 2020, and 30,238 vested on February 14, 2021.

Remarks:

Executive Vice President, International Markets Commercial

	/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)